Enzymes of the nasal tissue, one of the first tissues to contact inhaled toxicants, are relatively resistant to induction by traditional inducers. Because tobacco smoke has been shown to induce cytochrome P450 1A1 (CYP1A1) in rat and human lung tissue, we hypothesized that it would also alter levels of xenobiotic-metabolizing enzymes in nasal mucosae. In the present study, the effect of mainstream cigarette smoke (MCS) on nasal CYP1A1, CYP1A2 and CYP2B1/2 was explored. Four groups of 30 F344 rats were exposed to MCS (100 mg total particulate matter/m 3 ) or filtered air for 2 or 8 weeks. Western analysis of microsomes from nasal tissue of MCS-exposed rats showed an induction of CYP1A1 in respiratory and olfactory mucosae, as well as liver, kidney and lung. Relative to controls, CYP1A2 levels increased slightly in the liver and olfactory mucosa. CYP2B1/2, which increased in the liver, appeared to decrease in upper and lower respiratory tissues. Little to no immunoreactivity with CYP1A1 antibody was observed in fixed nasal sections of control rats, yet intense immunoreactivity was seen in epithelia throughout the nasal cavity of MCS-exposed rats. Ethoxyresorufin O-deethylase activity (associated with CYP1A1/2) decreased~2-fold in olfactory mucosa, but increased in non-nasal tissues of rats exposed to MCS. Methoxy-and pentoxyresorufin O-dealkylase activities (associated with CYP1A2 and CYP2B1/2, respectively) decreased in olfactory and respiratory mucosae, as well as lung (CYP2B1/2), yet increased in liver. These data suggest that xenobiotic-metabolizing enzymines of the nasal mucosae may be regulated differently than other tissues.
Introduction
Cigarette smoking has long been associated with increased risk of certain cancers and an overall increase in mortality (1) . Studies of cigarette smoke have revealed it to be mutagenic and carcinogenic in its unfractionated form (2, 3) . When fractionated, the neutral extract of the particulate component of cigarette smoke was found to have the greatest tumorigenic activity (1) . With the identification and quantification of Ͼ3000 chemical compounds in cigarette smoke, this neutral fraction was found to contain such known carcinogens as benzo [a] pyrene (BaP*) and dibenzo [a] anthracene (polycyclic aromatic hydrocarbons), as well as certain chlorinated hydrocarbon pesticides. The mutagenicity of the neutral fraction in Salmonella typhimurium requires the addition of activating enzymes contained in rat liver S-9 fractions (2). The enzymatic metabolism of these mutagenic components of cigarette smoke appears to produce compounds that readily form adducts with DNA and other cellular macromolecules. Such DNA adduct formation is thought to be the primary initiating event for subsequent carcinogenic events. Therefore, the location, quantity and specificity of xenobiotic-metabolizing enzymes in normal and cigarette smoke-exposed tissues may be indicative of the risk and site of occurrence of smokeinduced cancers.
The effects of cigarette smoke on the xenobiotic-metabolizing enzymes of the nasal tissues are of particular interest because of the role of the nasal epithelium as the site of initial contact with inhaled toxicants, often at concentrations several orders of magnitude greater than those encountered by other tissues. Exposure of experimental animals to cigarette smoke produces significant increases in DNA adduct formation in the nasal tissues (4), while numerous chemicals found in cigarette smoke, such as formaldehyde, vinyl chloride, N-nitrosodiethylamine, BaP and certain tobacco-specific nitrosamines, induce nasal tumors in animals following inhalation exposure (5) (6) (7) (8) (9) . Cigarette smoking is associated in humans with an increased risk of cancers of the nasal cavity, sinuses and pharynx (10, 11) .
In addition, the xenobiotic-metabolizing enzymes of the nasal tissues are postulated to play a role in the process of olfaction, possibly producing odorants from non-odorants, or metabolizing odorants to non-odorants to regenerate free olfactory receptors (12) . For this reason, changes in levels or activity of these nasal enzymes in response to cigarette smoke exposure could not only affect the carcinogenic process in these tissues, but could also play a role in the development of the olfactory deficits detected in smokers and former smokers (13) .
This participation in detoxification and olfaction may explain the response of these nasal enzymes to inducers, a response that often differs significantly from the response of hepatic enzymes. Classic inducers of liver enzymes, such as phenobarbital, BaP, trichlorobenzo-p-dioxin and 3-methylcholanthrene, have little or no effect on nasal enzyme levels (14) (15) (16) (17) . Such differences in regulation suggest that in order to understand nasal enzyme functions and the consequences of changes in them, it is necessary to examine the nasal tissues, rather than extrapolate from observations in other tissues. Exposure to cigarette smoke has been reported to alter cytochrome P450 protein levels and associated enzyme activities in liver, kidney and lung of experimental animals, as well as humans. Therefore, this study was conducted to test the hypothesis that inhalation exposure of rats to mainstream cigarette smoke (MCS*) alters P450 protein levels and enzymatic activities in rat nasal mucosae.
Materials and methods

Animals and exposures
Male F344/Crl rats [CDF ® (F344)/CrlBR rats; Charles River Laboratories, Raleigh, NC] were obtained at 8-9 weeks of age; 120 rats were placed, one per cage, into whole-body inhalation chambers (H2000, Laboratory Products, Maywood, NJ) and supplied with filtered air for quarantine and conditioning. The chambers were maintained at 12 Ϯ 2 air changes/h, at a temperature of 24 Ϯ 2°C and relative humidity of 40-70%. Room lights were on a 12-h on/ off cycle. Food (Wayne Lab Blox, Allied Mills, Chicago, IL) and water were available ad libitum, except when food was withheld from all rats during the daily 6-h exposures. Rats were randomly assigned by weight to experimental groups and observed for clinical signs of toxicity twice daily during quarantine and exposure periods. Exposure to MCS or filtered air for either 2 or 8 weeks was begun when the rats were 11 to 13 weeks old.
Diluted MCS was generated from 1R3 research cigarettes (Tobacco and Health Research Institute, Lexington, KY) by modified AMESA Type 1300 automated smoking machines (AMESA, Geneva, Switzerland) as previously described (18) . Cigarettes were held at 24°C and 50-70% relative humidity before use, then puffed twice/min at a 70 ml puff volume taken over 2 s. Each cigarette was puffed 6-7 times. The fresh smoke was diluted with filtered air prior to delivery to the exposure chambers. The target mass concentration of MCS total particulate matter (TPM) was 100 mg TPM/m 3 . Actual mean concentrations were 119 mg TPM/m 3 for the rats exposed for 2 weeks and 110 mg TPM/m 3 for the rats exposed for 8 weeks. CO concentrations were measured periodically using an infrared analyzer (Beckmann Industries, La Habra, CA). During the course of this and other studies (19) , Ͼ400 CO measurements were taken in chambers containing MCS. The line fitted to the CO versus mg TPM/m 3 data gave the relationship: (CO p.p.m.) ϭ 0.90* (mg TPM/m 3 ), thus giving a nominal CO concentration of 90 p.p.m. at 100 mg TPM/m 3 . MCS particulate size as determined by cascade impaction was 0.52 µm (Ϯ0.05 SD) with a geometric SD of 1.42 (Ϯ0.04 SD) averaged over seven individual measurements. The chemical characteristics of the MCS exposures have been described elsewhere (20) . Exposures were conducted daily for 6 h/day. Filtered air controls were held in a separate chamber in the same room. Tissue preparation Rats whose tissues were used for microsome preparation were anesthetized with sodium pentobarbital and killed by exsanguination. The livers, lungs and kidneys were removed and placed in cold saline. Nasal cavities were opened and the olfactory and respiratory (with transitional) mucosae removed and rinsed with cold saline. S9 homogenates were prepared from the nasal tissues, liver, lung and kidneys according the method of Leakey and coworkers (21) . In brief, the tissues were placed in buffer composed of 10 mM HEPES, pH 7.4, 250 mM sucrose, 25 mM KCl, 1 mM dithiothreitol, 0.5 mM EDTA, 10% (v/v) glycerol and homogenized. The homogenate was centrifuged at 9000 g for 20 min at 4°C. The supernatant was removed and frozen at -80°C. Liver and lung S9 homogenates were prepared from tissues of individual rats, while kidney and nasal S9 homogenates were prepared from pooled tissues (five rats per pool). Microsomes were obtained by centrifugation of the S9 homogenates for 60 min at 100 000 g and resuspension of the resulting pellet in 0.1 M Tris-HCl, pH 7.4, 1.15% KCl prior to measurement of enzymatic activities and immunoblot analysis. Microsomal protein concentrations were determined by the biuret method using reagents purchased from Sigma (St Louis, MO).
Rats whose tissues were used for immunohistochemistry were anesthetized with 4% halothane in oxygen and killed by severing the abdominal aorta. The nasal cavity was fixed with 10% zinc-formalin for 24 h, decalcified in 13% formic acid for 3 days, and then embedded in paraffin. The nasal cavity was transversely sectioned at four specific anatomic locations, as described by Young (22) : (i) immediately posterior to the upper incisor teeth (section T 1 ), (ii) at the level of the incisor papilla (section T 2 ), (iii) at the level of the second palatine ridge (section T 3 ), and (iv) at the level of the first upper molar teeth (section T 4 ). Sections (5 µm) were cut from the anterior face of each nasal tissue block and mounted on ProbeOn Plus slides (Fisher).
Measurement of ethoxy-, methoxy-and pentoxyresorufin O-dealkylase activity
The metabolism of ethoxyresorufin is associated with cytochromes P450 1A1 (CYP1A1) and 1A2, with CYP1A1 metabolizing ethoxyresorufin to a much greater extent than CYP1A2 when both P450s are present. Methoxyresorufin dealkylation is thought to be carried out solely by CYP1A2, while the dealkylation of pentoxyresorufin is attributed to CYP2B1/2.
656
The dealkylation of ethoxy-, methoxy-and pentoxyresorufin by microsomes was quantitated by measurement of increased resorufin fluorescence over time using a F-1200 Hitachi fluorimeter (excitation λ ϭ 535 nm, emission λ ϭ 586 nm) equipped with a Houston Instruments OmniScribe chart recorder. The reactions were carried out in a quartz cuvette (1-cm path length) and a total volume of 1.2 ml. Microsomal protein (30-90 µg) was added to 0.1 M potassium phosphate buffer, pH 7.6, along with 2 µM ethoxy-, methoxy-or pentoxyresorufin (Molecular Probes, Eugene, OR). This microsome-substrate solution was then incubated for 2 min at 37°C prior to initiation of the reaction with 0.5 mM NADPH (Sigma). The dealkylation reaction was allowed to proceed for 1 min at room temperature before initiating fluorescence measurements. Fluorescence was measured continuously for the next 3 min. The rate of formation of resorufin was calculated by comparing the relative rate of increase in fluorescence over this time period with the fluorescence of known amounts of resorufin.
Western blot analysis
Immunoblots were prepared by subjecting 5-10 µg of microsomal protein to electrophoresis on a 10% sodium dodecyl sulfate (SDS)-polyacrylamide gel. The proteins were then transferred to a nitrocellulose membrane by means of a tank-transfer system. The protein blots were incubated overnight at 4°C in a blocking solution of Tris buffered saline pH 7.6 (TBS) ϩ 5% (w/v) dehydrated skim milk (Difco Laboratories, Detroit, MI). Blots were incubated with primary antibody at room temperature for 2 h with antibodies diluted 1:200-2500 in TBS ϩ 1% (w/v) dry milk. Partially purified antigen-specific rabbit anti-rat CYP1A1, CYP2B1/2 and CYP3A1 antibodies were purchased from XenoTech (Kansas City, KS). Partially purified rabbit anti-rat CYP1A2 antibody was obtained from Amersham (Arlington Heights, IL). Following incubation with primary antibody, the blots were rinsed with TBS ϩ 0.1% Tween-20 (TTBS) and incubated for 1 h at room temperature with biotinylated goat anti-rabbit IgG (Vector Laboratories, Burlingame, CA) diluted 1:1000 in TBS/1% milk. After rinsing with TTBS, the blots were incubated for 20 min at room temperature with streptavidin-conjugated horseradish peroxidase (Amersham) diluted 1:2000 in TBS/1% milk. The blots were then rinsed with TTBS, incubated with Amersham ECL detection reagents, and exposed to film as instructed in the Amersham protocol. Some of the initial blots were developed by incubation with 3,3Ј-diaminobenzedine (DAB) as described below, rather than by the ECL method. Fotodyne's Collage 3.0 software and a Foto/Eclipse camera were used to quantify the results.
Immunohistochemistry
Nasal tissue sections (T 1 -T 4 ) were immunohistochemically stained to detect CYP1A1 using partially purified rabbit anti-rat CYP1A1. The sections were deparaffinized in xylene and rehydrated through a graded series of ethanol/ H 2 O baths. Sections were then incubated for 30 min at room temperature in 0.6% hydrogen peroxide in methanol to inhibit endogenous peroxidase activity, rinsed in H 2 O, and equilibrated in 1:10 Automation Buffer (AB; Biomeda Corp., Foster City, CA). The slides were transferred to a MicroProbe slide holder for application of subsequent reagents by means of capillary action (MicroProbe Manual Staining System, FisherBiotech). The sections were incubated for 2 h at room temperature with a blocking solution composed of 1.5% normal goat serum in 1:10 AB, followed by incubation overnight at 4°C with primary antibody diluted 1:1000 in Primary Antibody Diluting Buffer (PADB, Biomeda). Serial, identically treated sections were incubated with partially purified rabbit anti-rat CYP3A1 as immunostaining controls. Because the CYP1A1 antibody was partially purified, an antibody prepared and purified using the same techniques and used at the same concentration was deemed a more appropriate control than either normal rabbit serum or purified rabbit immunoglobulin. After warming to room temperature, the sections were rinsed with 1:10 AB and incubated for 1 h with biotinylated goat anti-rabbit IgG (Vector Laboratories) diluted 1:200 in PADB. After rinsing with 1:10 AB, the sections were incubated for 1 h at room temperature with Avidin DH: biotinylated horseradish peroxidase H complex in 1:10 AB as described in the instructions accompanying the VectaStain Elite ABC kit (Vector Laboratories). The sections were rinsed, and a DAB solution was prepared and applied as instructed (DAB Substrate kit, Vector Laboratories). After removal of this solution, the sections were rinsed with H 2 O, counterstained with hematoxylin, dehydrated and preserved.
Statistical analysis
Student's t-test was used to determine the significance of observed differences between the control and MCS-exposed groups of rats. Single comparisons were made between the two groups with the experimental conditions for each group differing by only one variable (presence or absence of MCS); therefore, no corrections to this test were deemed necessary. Comparisons resulting in a P-value Ͻ0.05 were considered significant and referred to as such. Comparisons resulting in a P-value Ͻ0.25 were referred to as not significant, 
Results
Effect of cigarette smoke on alkoxyresorufin O-dealkylase activities
Assay results showed significant changes (P Ͻ 0.05) in one or more of the alkoxyresorufin O-dealkylase activities in all five tissues examined following both 2 (Table I ) and 8 weeks (Table II) of MCS exposure. Liver samples from exposed rats showed significant increases in methoxyresorufin O-dealkylase (MROD) and pentoxyresorufin O-dealkylase (PROD) activities after 2 weeks, with all three activities increasing significantly after 8 weeks of exposure. Lung samples displayed significant changes in ethoxyresorufin O-deethylase (EROD) and PROD activities following both 2 and 8 weeks of exposure. Essentially no MROD activity was detected in the lung samples, as would be expected because CYP1A2 has not been shown to be present in the lung. CYP1A2 and CYP2B1/2 are also not thought to be present in kidney. Their absence was supported by assay results that showed low, unchanging MROD and PROD activities in kidney samples from control and MCSexposed rats, yet EROD activity increased significantly in kidney microsomes following both 2 and 8 weeks of exposure. The enzyme activities detected in the nasal samples varied more than the other tissues, which is unexpected in that each nasal sample was prepared from a pool of nasal tissues from five rats, rather than from an individual rat as in the case of liver and lung. Using stringent criteria (P Ͻ 0.05), a significant decrease in enzymatic activity after 2 weeks of MCS exposure was seen only with PROD activity in olfactory tissue. All three dealkylating activities decreased significantly in the olfactory mucosa after 8 weeks of MCS exposure, with PROD activity in the respiratory mucosa also decreasing significantly after 8 weeks. Less stringent analysis (P Ͻ 0.25) suggests a decrease in olfactory EROD activity after only 2 weeks, and decreases in respiratory MROD and PROD activities after both 2 and 8 weeks of exposure.
Effect of cigarette smoke on CYP1A1, CYP1A2 and CYP2B1/ 2 protein levels
The effect of MCS exposure on CYP1A1, CYP1A2 and CYP2B1/2 protein levels was determined by Western analysis of microsomes prepared from the tissues of rats exposed to MCS or filtered air for 2 and 8 weeks (Figure 1 ). Significant induction of CYP1A1 was found in all tissues examined as a result of MCS exposure (Figure 2) , with the greatest increase in antigenic protein in lung and nasal respiratory tissue, and the greatest increase in all tissues occurring after 8 weeks of exposure.
As expected from previous reports and the results of the MROD assays, no CYP1A2 protein was detected in lung or kidney. CYP1A2 was detected in liver, however. The observed increase in the liver as a result of MCS exposure was not statistically significant, but was observed after both 2 and 8 weeks of exposure, as was a corresponding increase in MROD activity. CYP1A2 was also detected in nasal respiratory and olfactory mucosae, where antigenic CYP1A2 may have increased in the olfactory mucosa after 8 weeks of MCS exposure (P Ͻ 0.20).
CYP2B1/2 protein was not detected in kidney, but was detected in all other tissues examined. Higher levels were measured in all tissues after 8 weeks of air and MCS exposure; however, as this was true of control as well as exposed rats, no conclusions can be drawn regarding the effect of increased MCS exposure on CYP2B1/2. In the liver, antigenic CYP2B1/2 increased relative to the control samples as a result of 8 weeks of MCS exposure (P Ͻ 0.10), while in the lung, CYP2B1/2 protein levels remained unchanged. CYP2B1/2 levels in the nasal respiratory and olfactory mucosae appeared to decline as a result of MCS exposure. This was suggested statistically only in the respiratory mucosa after 2 weeks of exposure (P Ͻ 0.20). This decline was seen, however, in both nasal tissues (respiratory and olfactory) following both 2 and 8 weeks of exposure. Along with the corresponding decreases in PROD activity in those samples, both findings support a decrease in CYP2B1/2 protein levels in rat nasal tissues as a result of exposure to cigarette smoke. 
Nasal histopathology
Histologic examination of nasal sections from filtered air-and MCS-exposed rats revealed no lesions in the nasal mucosae of filtered air-exposed rats. There were multifocal hyperplasia and non-cornified squamous metaplasia of the transitional epithelium lining the medial and lateral aspects of the maxilloturbinates, the lateral walls and the lateral aspects of the nasal turbinates in the anterior nose (T 1 sections) of rats exposed to MCS for 2 weeks. Minimal, scattered, individual cell necrosis and de-squamation of individual cells were present in this region. After 8 weeks of exposure, the non-cornified squamous metaplasia was slightly more extensive in the transitional epithelium of the T 1 sections, and cell necrosis and desquamation were less. There was minimal hyperplasia of the respiratory epithelium lining the mid-and ventral septum of rats exposed to MCS for 2 and 8 weeks. Lesions were not evident in tissue sections 2, 3 and 4.
Immunohistochemical localization of CYP1A1 in nasal tissue
Immunohistochemical detection of CYP1A1 in nasal sections of rats exposed to filtered air showed no CYP1A1 immunoreactivity in the squamous epithelium of the nasal vestibule or in the transitional epithelium ( Figure 3A and C) of control rats. There was faint immunostaining of the apices of scattered Fig. 2 . CYP1A1 protein levels in the (A) liver (Liv), lung and kidney (Kid), and (B) liver, nasal respiratory mucosa (Resp) and olfactory mucosa (Olf) of 2-week filtered air-exposed (C) and MCS-exposed (E) rats, resulting from the incubation of microsomal protein blot (5 µg/lane) with CYP1A1-specific antibody and visualization with Amersham ECL kit. Lanes 1 contain molecular weight standards. Lanes 2 (3MC) contain 0.1 µg 3-methylcholanthrene-induced rat liver microsomal protein (XenoTech). Liver and lung microsomes were prepared from individual rats; kidney and nasal microsomes were prepared from pools of tissues from five rats.
serous cells in the respiratory epithelium ( Figure 3E ). This immunoreactivity was most evident in the anterior nose (T 1 and T 2 sections) where respiratory epithelium is most abundant, but it was also present in those relatively small portions of the posterior nose that are lined by respiratory epithelium. Immunostaining of a mucous cell was rare. Most of the olfactory mucosa did not exhibit CYP1A1 immunoreactivity in control rats ( Figure 3G ). A few, widely scattered, sustentacular cells in the olfactory epithelium were immunoreactive. Neither epithelial basal cells, glands nor endothelial cells in the lamina propria were immunoreactive in nasal mucosae of control rats.
CYP1A1 immunoreactivity was present in more nasal mucosal cell types of rats exposed to MCS than in control rats, and it was more intense. It was present in the same cell types of rats exposed to MCS for 2 and 8 weeks, but it was more intense at 8 than at 2 weeks. There was multifocal immunostaining of non-cornified cells in the squamous epithelium lining the nasal vestibule of rats exposed to MCS for 2 and 8 weeks. There was multifocal, locally extensive immunostaining of cuboidal, basal and squamous cells lining the medial and lateral aspects of the maxilloturbinates, the lateral walls, and the lateral aspects and ventral margin of the nasal turbinates in the anterior nose (a region normally lined by transitional epithelium) of rats exposed to MCS for 2 weeks. There was diffuse immunostaining of the epithelium in this region in rats exposed to MCS for 8 weeks (Figure 3B and D). In the respiratory epithelium, there was CYP1A1 immunostaining of basal, serous, ciliated and mucous cells ( Figure 3F ). The immunostaining was most intense and consistently present in basal and serous cells. It was usually less intense and variably present in ciliated and mucous cells. Overall, the respiratory epithelium exhibited greater immunoreactivity at 8 than at 2 weeks, as there were more cells with denser immunostaining. Endothelial cells in the lamina propria of transitional and respiratory mucosae exhibited CYP1A1 immunoreactivity after 2 and 8 weeks of MCS exposure ( Figure 3F ). The olfactory epithelium exhibited multifocal immunostaining primarily due to staining of the apical portion of sustentacular cells in these foci ( Figure 3H ). There was immunostaining of intraepithelial duct cells of Bowman's glands and faint immunostaining of the basal portions of some sustentacular cells. More sustentacular cells exhibited immunoreactivity at 8 weeks than at 2 weeks.
There was no CYP3A1 immunoreactivity, used as an immunohistochemical staining control, in squamous, transitional or respiratory mucosae of control or MCS-exposed rats. There was some staining of sustentacular cells and diffuse, moderate staining of Bowman's glands in the olfactory mucosae. This CYP3A1 immunoreactivity was not greater in MCS-exposed than control rats.
Discussion
The effect of cigarette smoke on nasal P450s has not been investigated, and relatively little is known of the effects of other possible inducers on nasal P450s. In contrast to the P450s of liver, lung and kidney, nasal P450s have proved to be largely resistant to induction by 'classic' xenobiotic inducers of extranasal enzymes such as phenobarbital, BaP, β-naphthoflavone (βNF), 3-methylcholanthrene (3MC) and others. CYP1A1, for example, is readily induced in the liver by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), isosafrole and polycyclic aromatic hydrocarbons such as BaP and 3MC. However, i.p. injections of BaP and 3MC did not increase aryl hydrocarbon hydroxylase (AHH) activity in nasal tissue (15) . In the same study, TCDD administration resulted in only a 2-fold increase in the AHH activity of nasal microsomes, compared with another study in which 1/3 of the amount of TCDD induced lung CYP1A1 45-fold (23) . βNF induces CYP1A2 mRNA, but not CYP1A1 mRNA, in rat ethmoturbinates, in contrast to hepatic tissue in which βNF is an effective inducer of both CYP1A1 and CYP1A2 (24) . In Bond's (15) study, i.p. injection of Arochlor 1254 did not induce AHH activity in nasal microsomes. However, subsequent studies demonstrated an increase in immunodetectable CYP1A1 and BaP-hydroxylase activity in nasal tissue following treatment with Arochlor 1254 (16, 25) .
The response of nasal CYP1A1 to cigarette smoke proved to be an exception of nasal P450 resistance to induction. Immunodetectable CYP1A1 in the nasal tissues increased significantly as a result of MCS exposure. Undetectable in any control tissue, CYP1A1 levels in the nasal respiratory mucosa after 8 weeks of MCS exposure were higher than in any other tissue and~five times greater than the induced level in liver. This induction of CYP1A1 by MCS is perhaps most striking when observed immunohistochemically, where little to no CYP1A1 immunoreactivity was observed in nasal sections from air-exposed control rats, yet intense CYP1A1 immunoreactivity was observed in nasal epithelia throughout the nose of MCS-exposed rats, with induction occurring in the absence of any morphologic changes in all but the most anterior section of the nasal cavity. Surprisingly, CYP1A1-associated EROD activity in the nasal respiratory and olfactory mucosae did not increase and actually decreased significantly in the olfactory mucosa. The highest specific activity for EROD was measured in air-exposed (control) olfactory mucosa, yet CYP1A1 was not detected in this sample (or any other control sample) by Western analysis. Similarly, in the nasal respiratory mucosa, the site of significant induction of CYP1A1 protein, EROD activity remained relatively unchanged following MCS exposure. Immunodetectable CYP1A2 increased or remained unchanged in the nasal tissues. MROD measurements, however, indicate a possible decrease in MROD activity in the respiratory mucosa, with a significant decrease in the olfactory mucosa following MCS exposure. This suggests that like CYP1A1, nasal CYP1A2 protein levels and associated alkoxyresorufin dealkylation do not respond in a related manner to cigarette smoke exposure.
CYP2B1/2 declined in both nasal respiratory and olfactory mucosae following MCS exposure. A similar decline in CYP2B1/2 was observed in the lung, indicating an overall response in the respiratory tissues that differed from the response in the liver where CYP2B1/2 levels increased in exposed rats. Similar to the immunodetectable CYP2B1/2, PROD activity also declined in the nasal tissues as a result of MCS exposure.
In the extranasal tissues, the observed induction of CYP1A1 protein and associated EROD activity by MCS exposure is supported by previously reported data. Numerous studies have reported an increase in CYP1A1-associated AHH activity in rat lung and kidney following inhalation exposure to cigarette smoke (26) (27) (28) , with some reporting a similar increase in liver AHH activity (29, 30) . Rat liver and lung EROD activities have also been shown to increase with exposure to cigarette smoke (31), while immunodetectable CYP1A1 protein has been reported to be induced in lung and liver of rats and mice as a result of smoke exposure (32, 33) . In humans, clinical studies have shown an association between cigarette smoking and increased lung AHH and liver EROD activities (34,35), as well as increased immunodetectable CYP1A in the liver and expression of CYP1A1 mRNA in the lung (36, 37) .
Less has been published regarding the effects of cigarette smoke on hepatic, pulmonary and renal CYP1A2 and CYP2B1/2. The observed induction of MROD activity and the probable induction of immunodetectable CYP1A2 in the liver correspond with previous reports of increased MROD activity and CYP1A2 protein in rat liver following smoke exposure (31, 32) . The observed increase in immunodetectable CYP2B1/2 in the liver and the decrease observed in CYP2B1/ 2-associated PROD activity in the lung have also been reported (32, 31) , but in contrast to our results, no increase in liver PROD was observed. Villard and colleagues (33) , who conducted a similar study in mice, also did not see a significant increase in liver PROD following cigarette smoke exposure, perhaps due to a shorter exposure time.
In general, changes observed in liver, lung and kidney P450 protein levels were accompanied by corresponding changes in their associated enzyme activities, yet in the nasal mucosae, the effect of MCS exposure on the enzyme activities associated with CYP1A1 and CYP1A2 did not correspond to changes in CYP1A1/2 protein levels. An adverse effect of MCS on an accessory enzyme or cellular pathway that is commonly required by all P450s may account for this effect. This is suggested by the observed decrease in alkoxyresorufin metabolism with MCS exposure, regardless of alkyl group, associated P450 and observed change in P450 protein levels. This effect could not be accounted for by a change in the levels of cytochrome P450 reductase, however. Antigenic cytochrome P450 reductase levels were not altered in the nasal mucosae (or any other tissues examined) as a result of MCS exposure (data not shown). The presence in the nasal tissues of an alkoxyresorufin-metabolizing enzyme not recognized by the antibodies used for Western and immunohistochemical analysis would also account for the lack of correlation between protein levels and enzyme activities. CYP2A3, for example, is a P450 found predominantly in rat nasal tissue that is active toward a number of different compounds. The metabolism of ethoxyresorufin by this P450 would result in a discrepancy between CYP1A1 protein levels and EROD activity if CYP2A3 protein levels decreased as a result of MCS exposure. Nasal CYP2A3 levels have recently been shown to decrease in the rat following administration of coumarin (38) . Altered CYP1B1 levels in the nose might also produce a discrepancy between enzyme levels and activities. An antibody against CYP1B1, generously provided by Dr Colin Jefcoate of the University of Wisconsin, was used to investigate whether this recently discovered polycyclic aromatic hydrocarbon-metabolizing enzyme is present in the nasal tissues, but no antigenic protein was detected in either control or MCS-exposed nasal samples (data not shown). Another possible explanation is the existence of CYP1A isoforms in the nasal tissues that differ in sequence, structure or function from those of other tissues in such a way that alkoxyresorufin metabolism is not an accurate indicator of the presence of these isoforms in the nasal tissues, perhaps as a result of a change in substrate specificity.
Interestingly, other researchers have reported similar discrepancies between CYP1A protein levels and enzyme activities. Sabourin et al. (39) detected little or no CYP1A1 in the nasal tissues of normal rabbits by immunoblot, yet measured significant EROD activity in the nasal mucosa. In an experiment with side-stream cigarette smoke, Kawamoto and colleagues (32) reported an induction of CYP1A1 in rat liver, but measured a decrease in AHH activity. The authors suggested the possible deactivation of the enzyme by CO or a reactive metabolite of some other component of cigarette smoke. And in a recently published study of cultured kidney cells (40) , exposure to BaP and TCDD was found to induce the expression of CYP1A1 mRNA and AHH activity, but not EROD activity.
This lack of correlation between nasal CYP1A and associated enzyme activities may warrant a re-examination of the induction of CYP1A in the nasal tissues by such inducers as TCDD, 3MC, Arochlor 1254 and BaP. Prior investigations into the effects of these compounds on the nasal enzymes relied on enzyme activity alone as an indicator of the extent of induction (15) . One report also included immunohistochemical analysis of treated tissues (16) ; however, it is likely that the antibody that was used recognized both CYP1A1 and CYP1A2, thus preventing the formation of definite conclusions regarding the effects of these compounds on individual P450 protein levels.
Such studies would address the need for increased knowledge of the regulation of P450s in the nasal mucosae. The correlation between cigarette smoking in humans and the occurrence of nasal cancer has been observed (10, 11) , but is poorly understood. The association of cigarette smoking and olfactory deficits supports the proposed participation of P450s in olfaction, possibly by metabolizing non-odorants into odorants or by metabolizing receptor-bound odorants to regenerate free receptors. Greater knowledge of the regulation of detoxicating enzymes in the nasal mucosae would aid in understanding the process of olfaction and the etiology of olfactory dysfunctions and associated diseases, as well as contribute to the understanding of the role P450s play in the bioactivation of compounds and the initiation of carcinogenesis.
